Rhumbline Advisers Theravance Biopharma, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 63,071 shares of TBPH stock, worth $628,817. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,071
Previous 77,084 18.18%
Holding current value
$628,817
Previous $653,000 22.21%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$7.66 - $10.25 $107,339 - $143,633
-14,013 Reduced 18.18%
63,071 $508,000
Q2 2024

Aug 01, 2024
SELL
$8.29 - $9.92 $125,137 - $149,742
-15,095 Reduced 16.38%
77,084 $653,000
Q1 2024

May 09, 2024
SELL
$8.22 - $11.59 $37,902 - $53,441
-4,611 Reduced 4.76%
92,179 $826,000
Q4 2023

Feb 08, 2024
SELL
$8.58 - $11.4 $54,706 - $72,686
-6,376 Reduced 6.18%
96,790 $1.09 Million
Q3 2023

Nov 09, 2023
SELL
$8.38 - $10.44 $20,723 - $25,818
-2,473 Reduced 2.34%
103,166 $890,000
Q2 2023

Aug 08, 2023
BUY
$10.16 - $11.92 $194,421 - $228,101
19,136 Added 22.12%
105,639 $1.09 Million
Q1 2023

May 11, 2023
BUY
$9.87 - $11.44 $31,041 - $35,978
3,145 Added 3.77%
86,503 $939,000
Q4 2022

Feb 14, 2023
BUY
$9.65 - $11.34 $26,344 - $30,958
2,730 Added 3.39%
83,358 $935,000
Q3 2022

Nov 10, 2022
BUY
$8.39 - $10.22 $48,225 - $58,744
5,748 Added 7.68%
80,628 $818,000
Q2 2022

Aug 11, 2022
BUY
$8.41 - $10.34 $98,371 - $120,946
11,697 Added 18.51%
74,880 $678,000
Q1 2022

May 12, 2022
BUY
$8.33 - $12.96 $5,431 - $8,449
652 Added 1.04%
63,183 $604,000
Q4 2021

Feb 10, 2022
BUY
$7.42 - $11.05 $12,480 - $18,586
1,682 Added 2.76%
62,531 $691,000
Q3 2021

Nov 12, 2021
BUY
$6.77 - $14.41 $16,505 - $35,131
2,438 Added 4.17%
60,849 $450,000
Q2 2021

Aug 05, 2021
SELL
$14.52 - $22.46 $45,070 - $69,715
-3,104 Reduced 5.05%
58,411 $848,000
Q1 2021

May 06, 2021
SELL
$16.57 - $21.08 $64,904 - $82,570
-3,917 Reduced 5.99%
61,515 $1.26 Million
Q4 2020

Feb 10, 2021
BUY
$14.89 - $20.16 $50,253 - $68,040
3,375 Added 5.44%
65,432 $1.16 Million
Q3 2020

Nov 12, 2020
SELL
$14.79 - $22.49 $130,151 - $197,912
-8,800 Reduced 12.42%
62,057 $918,000
Q2 2020

Aug 13, 2020
BUY
$20.64 - $30.69 $173,644 - $258,194
8,413 Added 13.47%
70,857 $1.49 Million
Q1 2020

May 06, 2020
BUY
$17.84 - $31.21 $80,779 - $141,318
4,528 Added 7.82%
62,444 $1.44 Million
Q4 2019

Feb 05, 2020
BUY
$16.12 - $25.89 $18,392 - $29,540
1,141 Added 2.01%
57,916 $1.5 Million
Q3 2019

Oct 23, 2019
SELL
$16.51 - $23.78 $4,870 - $7,015
-295 Reduced 0.52%
56,775 $1.11 Million
Q2 2019

Aug 14, 2019
BUY
$15.6 - $25.15 $29,172 - $47,030
1,870 Added 3.39%
57,070 $932,000
Q1 2019

May 01, 2019
SELL
$22.57 - $28.15 $13,158 - $16,411
-583 Reduced 1.05%
55,200 $1.25 Million
Q4 2018

Jan 31, 2019
BUY
$22.52 - $35.07 $422,295 - $657,632
18,752 Added 50.64%
55,783 $1.43 Million
Q3 2018

Nov 07, 2018
SELL
$22.83 - $32.67 $62,782 - $89,842
-2,750 Reduced 6.91%
37,031 $1.21 Million
Q2 2018

Aug 06, 2018
BUY
$22.06 - $25.52 $38,759 - $44,838
1,757 Added 4.62%
39,781 $902,000
Q1 2018

May 02, 2018
SELL
$23.37 - $29.71 $14,723 - $18,717
-630 Reduced 1.63%
38,024 $922,000
Q4 2017

Feb 09, 2018
SELL
$25.82 - $35.66 $197,884 - $273,298
-7,664 Reduced 16.55%
38,654 $1.08 Million
Q3 2017

Nov 06, 2017
BUY
$23.88 - $34.96 $1.11 Million - $1.62 Million
46,318
46,318 $1.59 Million

Others Institutions Holding TBPH

# of Institutions
122
Shares Held
47.3M
Call Options Held
200
Put Options Held
12.8K
View Full List

About Theravance Biopharma, Inc.

TBPH Quotes by TradingView
  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $666M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email